CAS 553-03-7 | 3,4-Dihydroquinolin-2(1H)-one | CAS Number 553-03-7

200,000+ products from a single source!

sales@angenechem.com

Product Categories

Home > Quinoline > 553-03-7

553-03-7 | 3,4-Dihydroquinolin-2(1H)-one

CAS No: 553-03-7 Catalog No: AG003IHA MDL No:MFCD00016722

Product Description

Catalog Number:

AG003IHA

Chemical Name:

3,4-Dihydroquinolin-2(1H)-one

CAS Number:

553-03-7

Molecular Formula:

C9H9NO

Molecular Weight:

147.1739

MDL Number:

MFCD00016722

IUPAC Name:

3,4-dihydro-1H-quinolin-2-one

InChI:

InChI=1S/C9H9NO/c11-9-6-5-7-3-1-2-4-8(7)10-9/h1-4H,5-6H2,(H,10,11)

InChI Key:

TZOYXRMEFDYWDQ-UHFFFAOYSA-N

SMILES:

O=C1CCc2c(N1)cccc2

UNII:

2CKG6TX32F

NSC Number:

49170

Properties

Complexity:

167

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

147.068g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

147.177g/mol

Monoisotopic Mass:

147.068g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

29.1A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

XLogP3:

1.1

Literature

Title	Journal
3-Eth-oxy-methyl-1,4-dihydro-quinolin-4-one.	Acta crystallographica. Section E, Structure reports online 20120701
Aflaquinolones A-G: secondary metabolites from marine and fungicolous isolates of Aspergillus spp.	Journal of natural products 20120323
Synthesis of tripeptide mimetics based on dihydroquinolinone and benzoxazinone scaffolds.	Chemistry (Weinheim an der Bergstrasse, Germany) 20111209
Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.	Journal of medicinal chemistry 20110811
2-(2-Chloro-6,7-dimethyl-quinolin-3-yl)-2,3-dihydro-quinolin-4(1H)-one.	Acta crystallographica. Section E, Structure reports online 20110801
Reactive spin state dependent enantiospecific photocyclization of axially chiral α-substituted acrylanilides.	Chemical communications (Cambridge, England) 20110307
Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).	Bioorganic & medicinal chemistry letters 20110301
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.	Bioorganic & medicinal chemistry letters 20101101
Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.	Bioorganic & medicinal chemistry letters 20100501
Ethyl 6-chloro-2-oxo-4-phenyl-1,2-dihydro-quinoline-3-carboxyl-ate.	Acta crystallographica. Section E, Structure reports online 20091201
Synthesis of highly enantioenriched 3,4-dihydroquinolin-2-ones by 6-exo-trig radical cyclizations of axially chiral alpha-halo-ortho-alkenyl anilides.	Journal of the American Chemical Society 20091028
(RS)-3-Acetyl-2-methyl-4-(3-nitro-phen-yl)-1,4,5,6,7,8-hexa-hydro-quinolin-5-one.	Acta crystallographica. Section E, Structure reports online 20091001
Novel approach to 3,4-dihydro-2(1H)-quinolinone derivatives via cyclopropane ring expansion.	Organic letters 20090305
In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.	Journal of medicinal chemistry 20081225
Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug.	Drug metabolism and disposition: the biological fate of chemicals 20080601
Synthesis and biological activity of quinolinone and dihydroquinolinone p38 MAP kinase inhibitors.	Bioorganic & medicinal chemistry letters 20080315
Quinoline and derivatives at a tar oil contaminated site: hydroxylated products as indicator for natural attenuation?	Environmental science & technology 20070801
Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors.	Journal of medicinal chemistry 20070503
Development of potent, orally active 1-substituted-3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors.	Bioorganic & medicinal chemistry letters 20070115
Microsphere-based protease assays and screening application for lethal factor and factor Xa.	Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.geneste@abbott.com.	Bioorganic & medicinal chemistry letters 20060201
Synthesis of five-, six-, and seven-membered ring lactams by CpRh complex-catalyzed oxidative N-heterocyclization of amino alcohols.	Organic letters 20040805
Novel 3,4-dihydroquinolin-2(1H)-one inhibitors of human glycogen phosphorylase a.	Bioorganic & medicinal chemistry letters 20031215
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter: Part 3. A potential 5-HT transporter imaging agent, 3-(3-[18F]fluoropropyl)-6-nitroquipazine.	Bioorganic & medicinal chemistry 20031117
Radical ring closures of 4-isocyanato carbon-centered radicals.	The Journal of organic chemistry 20030404
Synthesis of 3-methoxycarbonylmethyl derivatives of dihydroquinolone and dihydrochromenone.	The Journal of organic chemistry 20010323
Synthesis and vasorelaxing evaluation of alpha-methylidene-gamma-butyrolactone bearing quinolin-2(1H)-one and 3,4-dihydroquinolin-2(1H)-one derivatives.	European journal of medicinal chemistry 20010101